AVITA Medical Inc (ASX: AVH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Avita Therapeutics Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $115.18 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 124.78 million
Earnings per share -0.186
Dividend per share N/A
Year To Date Return -53.36%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

AVITA Medical Inc (ASX: AVH)
Latest News

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

4 ASX healthcare shares at 52-week lows

A number of ASX healthcare shares just hit 52-week lows.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise such as the rising Xero share price over the past decade
Small Cap Shares

3 promising small cap ASX shares to watch

Keep an eye on these small cap shares...

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Earnings Results

Avita Medical (ASX:AVH) share price soars 23% as earnings stage a comeback

Shares in the regenerative medicine company are on the move today.

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Avita (ASX:AVH) share price jumps 6% following FDA approval

Avita shares are on the move after the FDA approved the company's flagship product.

Read more »

Rising share price chart.
Healthcare Shares

Why the AVITA (ASX:AVH) share price is charging higher today

AVITA delivered strong growth in the second quarter...

Read more »

Scientists in white coats look disappointed as the Starpharma share price falls today
52-Week Lows

Avita Medical (ASX:AVH) share price sinks to 52-week low despite ‘pivotal’ trial update

Shares in the medical company are down today, despite a positive update

Read more »

A male Avita Medical doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

Down 22% in a month: Why is the Avita Medical (ASX:AVH) share price sliding again today?

The Avita Medical share price isn't catching bids today...

Read more »

Frequently Asked Questions

Avita Therapeutics shares do not currently include a dividend payment. The company has made no announcements regarding paying a dividend in 2020.

No, Avita Therapeutics does not currently offer a dividend reinvestment plan (DRP).

AVH ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AVITA Medical Inc

Avita Therapeutics Inc (ASX: AVH) is a medical technology company that specialises in regenerative medicine. Avita’s leading product, the RECELL System, was developed to address unmet medical needs in burns. The RECELL System is used to prepare ‘spray-on skin cells’ by using a small amount of the patient’s own skin. This is a revolutionary way to treat severe burns and significantly reduces the amount of donor skin required.

RECELL was granted US Food and Drug Administration (FDA) approval in September 2018 for the treatment of acute thermal burns in patients 18 years and older. Since then, Avita has been undertaking studies to assess the use of the RECELL System in other applications. This includes the treatment of pediatric scald injuries, soft tissue reconstruction and vitiligo.

The Avita share price exploded in 2019, going from $0.081 to finish the year a phenomenal 696% higher at $0.645. With this, Avita earned itself a spot in the S&P/ASX 200 Index (ASX: XJO), as well as a place on many investors’ ASX watchlists.

AVH Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 May 2022 $1.57 $-0.02 -1.25% 149,088 $1.60 $1.63 $1.56
16 May 2022 $1.60 $0.01 0.63% 401,910 $1.62 $1.67 $1.59
13 May 2022 $1.58 $-0.15 -8.67% 337,315 $1.65 $1.67 $1.56
12 May 2022 $1.73 $0.13 8.13% 752,856 $1.51 $1.73 $1.48
11 May 2022 $1.60 $0.07 4.56% 314,690 $1.59 $1.62 $1.56
10 May 2022 $1.54 $-0.12 -7.27% 707,746 $1.51 $1.56 $1.51
09 May 2022 $1.65 $-0.09 -5.17% 384,307 $1.69 $1.71 $1.60
06 May 2022 $1.74 $-0.09 -4.92% 548,681 $1.75 $1.75 $1.69
05 May 2022 $1.83 $0.01 0.55% 259,657 $1.84 $1.86 $1.80
04 May 2022 $1.82 $-0.01 -0.54% 141,277 $1.83 $1.86 $1.79
03 May 2022 $1.84 $0.04 2.23% 308,272 $1.82 $1.95 $1.82
02 May 2022 $1.79 $-0.03 -1.65% 345,672 $1.80 $1.83 $1.74
29 Apr 2022 $1.82 $0.00 0.00% 268,341 $1.81 $1.85 $1.81
28 Apr 2022 $1.82 $-0.07 -3.70% 381,472 $1.83 $1.84 $1.81
27 Apr 2022 $1.89 $-0.04 -2.07% 511,470 $1.86 $1.90 $1.82
26 Apr 2022 $1.93 $-0.10 -4.93% 520,448 $2.00 $2.01 $1.93
22 Apr 2022 $2.03 $-0.03 -1.46% 324,640 $2.04 $2.06 $2.01
21 Apr 2022 $2.06 $0.00 0.00% 335,306 $2.06 $2.12 $2.05
20 Apr 2022 $2.06 $0.01 0.49% 232,793 $2.07 $2.09 $2.05

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
23 Dec 2021 Suzanne Crowe Issued 4 $15,051
Issue of securities. 4,350 - RSUs
23 Dec 2021 Suzanne Crowe Issued 2 $8,823
Issue of securities.
23 Dec 2021 Jeremy Curnock-Cook Issued 2 $8,823
Issue of securities.
23 Dec 2021 Jeremy Curnock-Cook Issued 4 $15,051
Issue of securities. 4,350 - RSUs
23 Dec 2021 Louis (Lou) Panaccio Issued 2 $8,823
Issue of securities.
23 Dec 2021 Louis (Lou) Panaccio Issued 4 $15,051
Issue of securities. 4,350 - RSUs
23 Dec 2021 Michael Perry Issued 95 $329,668
Issue of securities. 7,221,329 - RSUs
23 Dec 2021 Michael Perry Issued 55 $190,992
Issue of securities. As per announcement on 30/12/2021.
23 Dec 2021 Louis Drapeau Issued 2 $8,823
Issue of securities.
23 Dec 2021 Louis Drapeau Issued 4 $15,051
Issue of securities. 4,350 - RSUs
23 Dec 2021 Jan Reed Issued 13 $45,066
Issue of securities. 13,025 - RSUs
23 Dec 2021 Jan Reed Issued 7 $25,863
Issue of securities.
23 Dec 2021 James Corbett Issued 13 $45,066
Issue of securities. 13,025 - RSU's
23 Dec 2021 James Corbett Issued 7 $25,863
Issue of securities.
20 Sep 2021 Suzanne Crowe Buy 5 $25,166
On-market trade. CDIs
01 Sep 2021 Michael Perry Buy 2 $13,064,700
Conversion of securities. consolidation equivalent = 23,754 RSUs in Avita US
As per announcement on 09/09/2021
01 Sep 2021 Michael Perry Sell 11 $231,356
On-market trade. Average price
01 Sep 2021 Michael Perry Exercise 2 $13,064,700
Conversion of securities. 7,126,049 - RSUs
consolidation equivalent = 23,754 RSUs in Avita US
As per announcement on 09/09/2021.
04 Jun 2021 Michael Perry Exercise 4 $21,235,629
Conversion of securities. 9,501,400 - RSUs, (consolidation
equivalent = 95,014 unquoted RSUs
in Avita US)
As per announcement on 08/06/2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Louis (Lou) James Panaccio Non-Executive ChairmanNon-Executive Director Jul 2014
Mr Panaccio has served as Non-Executive Chairman of our Board of Directors since July 2014. Mr Panaccio is a healthcare businessman with experience leading companies from concept to commercialization. Mr. Panaccio possesses more than 30 years of executive leadership experience in healthcare services and life sciences, including more than 20 years of board-level experience. Mr Panaccio is currently a Non-Executive Director of ASX50 company and one of the world's largest medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005. In addition, Mr. Panaccio is NonExecutive Director of Unison Housing Limited, was Non-Executive Chairman of Genera Biosystems Limited until June 2019, and a Non-Executive Director of Rhythm Biosciences Limited, a publicly listed (ASX) development-stage medical diagnostics company.
Professor Suzanne Crowe Non-Executive Director Jan 2016
Ms Crowe has served as a Non-Executive Director of our Board of Directors since January 2016. Australian-based, she is a physician-scientist and ASX/NASDAQ-listed company director with expertise in supporting companies with their medical and scientific strategies. She is currently a Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostic company. Past board positions include St. Vincent's Health Australia Ltd (2012-2021), the country's largest not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia (AO) in 2020 in recognition of her services to health, clinical governance, biomedical research, and education.
Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
Mr Curnock Cook has served as a Non-Executive Director of our Board of Directors since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. As Founder and Managing Director of BioScience Managers, Mr Curnock Cook brings his decades of international experience to our Board of Directors, to support the identification of investment opportunities and in the strategic assessment of value creation options, in particular through M&A and expansion into new geographies. He actively supports portfolio companies through his executive and non-executive roles. Over his career, Mr Curnock Cook has successfully managed in excess of $1 billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. Mr Curnock Cook co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. Mr Curncock Cook has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan, and Australia. In addition to serving on our Board of Directors, Mr Curnock Cook serves on the following boards: REX Bionics appointed February 2012, Sea Dragon appointed October 2012, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, JLCC Ltd appointed December 2019, International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, Smart Matrix Ltd appointed February 2013, CRiL appointed November 2020, and Humanetix appointed September 2021.
Dr Michael S Perry Chief Executive OfficerExecutive Director Feb 2013
Mr Perry was appointed Chief Executive Officer and Executive Director in June 2017. He continues to serve in this role. Prior to this appointment, Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing 41 venture capital funds, based in San Francisco California. Dr Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines that treat intractable diseases by silencing genes. He is also a Venture Partner at BioScience Managers Pty Ltd.
Ms Jan Stern Reed Non-Executive Director Jul 2021
Mr Reed has served as a Non-Executive Director of our Board of Directors since July 2021. She has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Ms Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions. Prior to Solo Cup Company, she was Associate General Counsel, Corporate Secretary and Chief Corporate Governance Officer at Baxter International, Inc. Ms Reed currently serves as a board member of Stepan Co. (NYSE:SCL), a major manufacturer of specialty and intermediate chemicals used in a broad range of industries, and AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology.
Mr James Corbett Non-Executive Director Jul 2021
Mr Corbett has served as a Non-Executive Director of our Board of Directors since July 2021. He has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an expatriate General Manager of Baxter Japan and later as General Manager and President of Scimed Life Systems Inc. and Boston Scientific International respectively. During his career he has served as CEO of three publicly listed companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), Alphatec Spine (ATEC). Mr. Corbett has also led two privately funded companies as CEO: Home Diagnostics Inc. and Vertos Medical. Mr. Corbett has extensive capital market and governance experience from both public and private environments.
Mr Mark Andrew Licciardo Company Secretary Mar 2018
-
Erin Liberto Chief Commercial Officer
-
Michael Holder Chief Financial Officer
-
Kathy McGee Chief Operating Officer
-
Mark Andrew Licciardo Company Secretary
-
Donna Shiroma General Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
BlackRock Institutional Trust Company, N.A. 7,365,240 5.91%
Montgomery Investment Management Pty Ltd 6,989,810 5.61%
Redmile Group, LLC 6,731,085 5.40%
The Vanguard Group, Inc. 6,355,450 5.10%
Farallon Capital Management, L.L.C. 4,000,000 3.21%
State Street Global Advisors (US) 3,664,975 2.94%
Pura Vida Investments, LLC 3,340,715 2.68%
Blackcrane Capital, LLC 3,086,785 2.48%
Geode Capital Management, L.L.C. 2,109,600 1.69%
Norges Bank Investment Management (NBIM) 1,686,620 1.35%
RTW Investments L.P. 1,400,000 1.12%
Northern Trust Investments, Inc. 1,047,095 0.84%
Michael Perry 637,680 0.51%
Arlene Perry 631,525 0.51%
UBS Securities Australia Ltd. 626,450 0.50%
AustralianSuper - Member Direct 508,535 0.41%
Private Clients of Hub24 508,260 0.41%
XY Capital Limited 500,970 0.40%
BT Portfolio Services, Ltd. 487,815 0.39%
Allianz Global Investors U.S. LLC 440,735 0.35%

Profile

since

Note